Last edition
News about "Once-weekly subcutaneous therapy"
Pfizer Secures EC Approval to Expand Hympavzi Use for Haemophilia Patients with Inhibitors
Pfizer has secured European Commission approval to expand the use of Hympavzi for haemophilia A and B patients with inhibitors, offering a once-weekly subcutaneous treatment option designed to reduce bleeding episodes and improve disease management.
Once-weekly Subcutaneous Therapy | 14/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members